The Efficacy of Shen Shuaining Capsule on Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Abstract EN

Objective.

To evaluate the efficacy of Shen shuaining capsule on treating chronic kidney disease (CKD).

Methods.

All randomized controlled trials (RCTs) of Shen shuaining capsule in treating CKD were collected from CBM, CNKI, VIP, Wanfang, EMBASE, MEDLINE, PubMed, and Cochrane library clinical controlled trials database.

Two reviewers independently performed analysis of the included trials according to the inclusion and exclusion criteria.

The risk of bias tool was from the Cochrane Handbook version 5.1.0.

The Review Manager 5.2 software was employed for data analysis.

Funnel plot and Egger’s test were applied to evaluate publication bias.

Results.

20 studies including 1606 participants met the inclusion criteria, most of which were of low quality.

Meta-analysis indicated that Shen shuaining capsule was effective for CKD in terms of SCR, BUN, Hb, and response rate and with less adverse effects, of which SCR and BUN decreased significantly (MD = −84.72, 95% CI: −107.36, −62.07, P<0.00001) (MD = −4.30, 95% CI: −5.71, −2.89, P<0.00001); Hb and response rate increased significantly (MD = 9.94, 95% CI: 9.24, 10.64, P<0.00001) (OR = 4.25, 95% CI (3.32, 5.42), P<0.00001).

Conclusion.

Shen shuaining capsule significantly reduced SCR and BUN, increased HB, and improved total efficiency of the symptoms and signs in patients with CKD.

Subgroup analysis found that Shen shuaining capsule group was better than control group.

Due to low quality of the methodology of included studies, further high-quality researches were needed to study its efficacy and safety.